Calibr-Skaggs launched the first-in-human clinical study testing a modular 'switchable' CAR-T therapy platform designed to improve control and safety in solid tumor treatments. The Phase 1 trial evaluates CLBR001 T cells activated by the antibody switch ABBV-461 in advanced breast cancer patients. This approach permits external modulation of CAR-T activity, aiming to mitigate adverse effects while enhancing antitumor responses in challenging solid tumor environments.